Late bacille Calmette–Guérin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Intravesical BCG treatment has been used worldwide for many decades but there are only a few published reports on persisting BCG infection of the urinary bladder. This is the first...
Saved in:
Published in | BJU international Vol. 107; no. 10; pp. 1592 - 1597 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.05.2011
Wiley-Blackwell |
Subjects | |
Online Access | Get full text |
ISSN | 1464-4096 1464-410X 1464-410X |
DOI | 10.1111/j.1464-410X.2010.09923.x |
Cover
Abstract | Study Type – Therapy (case series)
Level of Evidence 4
What's known on the subject? and What does the study add?
Intravesical BCG treatment has been used worldwide for many decades but there are only a few published reports on persisting BCG infection of the urinary bladder.
This is the first report on large tuberculosis‐like ulcers of the urinary bladder after intravesical BCG treatment. The finding results in a recommendation to take urine cultures for mycobacteriae in patients with unclear inflammatory lesions in the bladder after instillation of BCG.
OBJECTIVE
•
To report a late bacille Calmette–Guérin (BCG) complication previously not described in the literature.
PATIENTS AND METHODS
•
We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous‐like bladder ulcer.
RESULTS
•
All patients had high‐grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10–50 mm in diameter, was seen at routine follow‐up cystoscopy 2–34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG‐RIVM than with BCG‐Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3–34 months (median 14 months) after the last instillation.
•
So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour‐free 15–66 months (median 44 months) after the last transurethral resection before BCG treatment.
•
Another three patients had one to two non‐invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design.
CONCLUSIONS
•
This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good.
•
Mycobacterial cultures of the urine should be performed in BCG‐patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity.
•
Large studies are warranted to study differences in efficacy and side‐effects between different BCG strains. |
---|---|
AbstractList | Study Type – Therapy (case series)
Level of Evidence 4
What's known on the subject? and What does the study add?
Intravesical BCG treatment has been used worldwide for many decades but there are only a few published reports on persisting BCG infection of the urinary bladder.
This is the first report on large tuberculosis‐like ulcers of the urinary bladder after intravesical BCG treatment. The finding results in a recommendation to take urine cultures for mycobacteriae in patients with unclear inflammatory lesions in the bladder after instillation of BCG.
OBJECTIVE
•
To report a late bacille Calmette–Guérin (BCG) complication previously not described in the literature.
PATIENTS AND METHODS
•
We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous‐like bladder ulcer.
RESULTS
•
All patients had high‐grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10–50 mm in diameter, was seen at routine follow‐up cystoscopy 2–34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG‐RIVM than with BCG‐Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3–34 months (median 14 months) after the last instillation.
•
So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour‐free 15–66 months (median 44 months) after the last transurethral resection before BCG treatment.
•
Another three patients had one to two non‐invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design.
CONCLUSIONS
•
This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good.
•
Mycobacterial cultures of the urine should be performed in BCG‐patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity.
•
Large studies are warranted to study differences in efficacy and side‐effects between different BCG strains. • To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature. • We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous-like bladder ulcer. • All patients had high-grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10-50 mm in diameter, was seen at routine follow-up cystoscopy 2-34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG-RIVM than with BCG-Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3-34 months (median 14 months) after the last instillation. • So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour-free 15-66 months (median 44 months) after the last transurethral resection before BCG treatment. • Another three patients had one to two non-invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design. • This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. • Mycobacterial cultures of the urine should be performed in BCG-patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. • Large studies are warranted to study differences in efficacy and side-effects between different BCG strains. • To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature.OBJECTIVE• To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature.• We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous-like bladder ulcer.PATIENTS AND METHODS• We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous-like bladder ulcer.• All patients had high-grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10-50 mm in diameter, was seen at routine follow-up cystoscopy 2-34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG-RIVM than with BCG-Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3-34 months (median 14 months) after the last instillation. • So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour-free 15-66 months (median 44 months) after the last transurethral resection before BCG treatment. • Another three patients had one to two non-invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design.RESULTS• All patients had high-grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10-50 mm in diameter, was seen at routine follow-up cystoscopy 2-34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG-RIVM than with BCG-Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3-34 months (median 14 months) after the last instillation. • So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour-free 15-66 months (median 44 months) after the last transurethral resection before BCG treatment. • Another three patients had one to two non-invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design.• This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. • Mycobacterial cultures of the urine should be performed in BCG-patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. • Large studies are warranted to study differences in efficacy and side-effects between different BCG strains.CONCLUSIONS• This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. • Mycobacterial cultures of the urine should be performed in BCG-patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. • Large studies are warranted to study differences in efficacy and side-effects between different BCG strains. Study Type - Therapy (case series) Level of Evidence 4 OBJECTIVE: To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature. PATIENTS AND METHODS: We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous-like bladder ulcer. RESULTS: All patients had high-grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10-50 mm in diameter, was seen at routine follow-up cystoscopy 2-34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG-RIVM than with BCG-Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3-34 months (median 14 months) after the last instillation. So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour-free 15-66 months (median 44 months) after the last transurethral resection before BCG treatment. Another three patients had one to two non-invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design. CONCLUSIONS: This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. Mycobacterial cultures of the urine should be performed in BCG-patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. Large studies are warranted to study differences in efficacy and side-effects between different BCG strains. |
Author | Ströck, Viveka Holmäng, Sten Dotevall, Leif Gustafsson, Christina Kåbjörn Sandberg, Torsten |
Author_xml | – sequence: 1 givenname: Viveka surname: Ströck fullname: Ströck, Viveka – sequence: 2 givenname: Leif surname: Dotevall fullname: Dotevall, Leif – sequence: 3 givenname: Torsten surname: Sandberg fullname: Sandberg, Torsten – sequence: 4 givenname: Christina Kåbjörn surname: Gustafsson fullname: Gustafsson, Christina Kåbjörn – sequence: 5 givenname: Sten surname: Holmäng fullname: Holmäng, Sten |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24165840$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21166754$$D View this record in MEDLINE/PubMed https://gup.ub.gu.se/publication/132360$$DView record from Swedish Publication Index |
BookMark | eNqNkk2O0zAUxy00iJkpXAF5g1il2HHipAuQoGIGUCU2jMTOenFfiivnA9tRZ3ZsOMGcgnNwE06C07RFYjXe2Pr79z70f--SnLVdi4RQzuY8nlfbOc9klmScfZ2nLKpssUjF_PYRuTh9nB3fbCHPyaX3W8aiIPMn5DzlXMoizy7IzxUEpBVoYy3SJdgGQ8A_P-6vh9-_nGmpaWvUwXQt3ZnwjQK14DZI606DpUMkwN3RysJ6jY4OVqODPQ0-srpremv0pHT1idPQRpAGhxAabMNT8rgG6_HZ4Z6Rm6v3X5YfktXn64_Lt6tEZ0KKBNfAq0KwLM_zEnQJFSuKXHJRwqKo0qLKCw1c5pkQhZAcy7oSWZkDVjUUuq7FjCRTXr_DfqhU70wT-1cdGLUZehWlzaA8Ki5SIVnkX05877rvA_qgGuM1WgstdoNXpRSFLFmEZ-T5gRyqBtenzEenI_DiAICP1tUuWmD8Py6LfZfZWPLNxGnXee-wVtqEvYHBgbGKMzWugNqqcbpqnLQaV0DtV0DdxgTlfwmONR4Q-noK3RmLdw-OU-8-3Ywv8RfIaMwE |
CitedBy_id | crossref_primary_10_1016_j_acuro_2022_08_001 crossref_primary_10_1016_j_ajur_2022_12_006 crossref_primary_10_1016_j_urology_2019_10_013 crossref_primary_10_1186_s13643_025_02761_y crossref_primary_10_1016_j_eururo_2020_01_017 crossref_primary_10_3233_BLC_239010 crossref_primary_10_1186_1471_2490_14_11 crossref_primary_10_1016_j_rmr_2017_11_010 crossref_primary_10_1259_bjr_20200025 crossref_primary_10_1080_21681805_2021_1973555 crossref_primary_10_2169_internalmedicine_4659_24 crossref_primary_10_1016_j_euo_2020_05_005 crossref_primary_10_1097_MOU_0b013e3283572fe1 crossref_primary_10_1016_j_acuroe_2022_09_003 crossref_primary_10_1097_MD_0000000000000119 crossref_primary_10_1155_2019_6230409 |
Cites_doi | 10.1111/j.1464-410X.2005.05817.x 10.1016/S0090-4295(96)00507-9 10.1016/S0022-5347(17)41212-2 10.1016/j.ctrv.2009.12.005 10.1111/j.1464-410X.1995.tb07309.x 10.1016/S0022-5347(01)67606-7 10.1080/003655900750016698 10.1111/j.1445-2197.1998.tb04768.x 10.1016/0090-4295(93)90595-2 10.1016/S0022-5347(17)37316-0 10.1080/00365540110077371 10.1046/j.1464-410x.1998.00578.x 10.1016/S0022-5347(05)66410-5 10.1016/S1473-3099(02)00182-2 |
ContentType | Journal Article |
Copyright | 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL 2015 INIST-CNRS 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL. |
Copyright_xml | – notice: 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL – notice: 2015 INIST-CNRS – notice: 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL. |
CorporateAuthor | Gothenburg University Sahlgrenska Academy Göteborgs universitet Institutionen för biomedicin, avdelningen för infektionssjukdomar Institute of Clinical Sciences, Section for Oncology, Radiation Physics, Radiology and Urology, Department of Urology Sahlgrenska akademin Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för urologi Institute of Biomedicine, Department of Infectious Medicine |
CorporateAuthor_xml | – name: Institutionen för biomedicin, avdelningen för infektionssjukdomar – name: Göteborgs universitet – name: Gothenburg University – name: Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för urologi – name: Sahlgrenska Academy – name: Institute of Biomedicine, Department of Infectious Medicine – name: Sahlgrenska akademin – name: Institute of Clinical Sciences, Section for Oncology, Radiation Physics, Radiology and Urology, Department of Urology |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS F1U |
DOI | 10.1111/j.1464-410X.2010.09923.x |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Göteborgs universitet |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1464-410X |
EndPage | 1597 |
ExternalDocumentID | oai_gup_ub_gu_se_132360 21166754 24165840 10_1111_j_1464_410X_2010_09923_x BJU9923 |
Genre | article Multicenter Study Journal Article |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 1OB 7X8 ADTPV AOWAS F1U |
ID | FETCH-LOGICAL-c4363-eda1b73045558ac8ab07756138a97b27b57ca1654337361e8fb3485aebfa7cff3 |
IEDL.DBID | DR2 |
ISSN | 1464-4096 1464-410X |
IngestDate | Tue Sep 09 21:02:48 EDT 2025 Thu Sep 04 23:51:58 EDT 2025 Mon Jul 21 05:38:09 EDT 2025 Mon Jul 21 09:18:28 EDT 2025 Tue Jul 01 03:49:49 EDT 2025 Thu Apr 24 23:12:09 EDT 2025 Wed Jan 22 16:50:16 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | Nephrology Late Urinary system disease complications BCG Urinary tract disease Malignant tumor Bladder cancer Bladder tumor Urology Infection Treatment Urinary system Urinary bladder Complication Bladder disease Ulceration bladder neoplasm Cystitis Cancer |
Language | English |
License | CC BY 4.0 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4363-eda1b73045558ac8ab07756138a97b27b57ca1654337361e8fb3485aebfa7cff3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 21166754 |
PQID | 863768032 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | swepub_primary_oai_gup_ub_gu_se_132360 proquest_miscellaneous_863768032 pubmed_primary_21166754 pascalfrancis_primary_24165840 crossref_citationtrail_10_1111_j_1464_410X_2010_09923_x crossref_primary_10_1111_j_1464_410X_2010_09923_x wiley_primary_10_1111_j_1464_410X_2010_09923_x_BJU9923 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2011 |
PublicationDateYYYYMMDD | 2011-05-01 |
PublicationDate_xml | – month: 05 year: 2011 text: May 2011 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
PublicationTitle | BJU international |
PublicationTitleAlternate | BJU Int |
PublicationYear | 2011 |
Publisher | Blackwell Publishing Ltd Wiley-Blackwell |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell |
References | 1995; 75 2001; 165 2006; 52 2010; 36 2000; 34 1989; 141 2002; 34 1992; 147 1993; 41 2005; 96 2002; 2 1997; 49 1998; 81 1995; 153 2007; 14 1998; 68 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_17_2 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_13_2 e_1_2_7_12_2 e_1_2_7_11_2 e_1_2_7_10_2 Hameed A (e_1_2_7_14_2) 2007; 14 Khanna PC (e_1_2_7_8_2) 2006; 52 |
References_xml | – volume: 165 start-page: 1765 year: 2001 end-page: 8 article-title: The fate of Bacillus Calmette‐Guérin after intravesical instillation publication-title: J Urol – volume: 153 start-page: 929 year: 1995 end-page: 33 article-title: A randomized study of intravesical mitomycin C, bacillus Calmette‐Guerin Tice and bacillus Calmette‐Guerin RIVM treatment in pTa‐pT1 papillary carcinoma and carcinoma in situ of the bladder publication-title: J Urol – volume: 2 start-page: 86 year: 2002 end-page: 92 article-title: BCG‐different strains, different vaccines? publication-title: Lancet Infect Dis – volume: 36 start-page: 195 year: 2010 end-page: 205 article-title: Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta‐analyses publication-title: Cancer Treat Rev – volume: 141 start-page: 1197 year: 1989 end-page: 8 article-title: Persistent acid‐fast bacilli following intravesical bacillus Calmette‐Guérin publication-title: J Urol – volume: 68 start-page: 340 year: 1998 end-page: 4 article-title: Bacillus Calmette‐Guérin (BCG) immunotherapy for bladder cancer: review of complications and their treatment publication-title: Aust N Z J Surg – volume: 81 start-page: 496 year: 1998 end-page: 7 article-title: Acid‐fast bacilli persisting in the genitourinary tract 3 years after intravesical bacilli Calmette‐Guérin therapy for bladder carcinoma publication-title: Br J Urol – volume: 14 start-page: 3745 year: 2007 end-page: 9 article-title: Bladder contracture: review for intravesical bacillus Calmette‐Guérin complication publication-title: Can J Urol – volume: 34 start-page: 233 year: 2002 end-page: 4 article-title: Early PCR detection of Bacille Calmette‐Guérin complications in bladder cancer therapy publication-title: Scand J Infect Dis – volume: 34 start-page: 95 year: 2000 end-page: 101 article-title: Prospective registration of all patients in a geographical region with newly diagnosed bladder carcinomas during a two‐year period publication-title: Scand J Urol Nephrol – volume: 52 start-page: 35 year: 2006 end-page: 7 article-title: Virtual cystoscopy: reality in imaging of bladder tuberculosis publication-title: J Postgrad Med – volume: 41 start-page: 353 year: 1993 end-page: 5 article-title: Bladder contracture following intravesical BCG immunotherapy publication-title: Urology – volume: 49 start-page: 363 year: 1997 end-page: 6 article-title: Incidence of granulomatous prostatitis and acid‐fast bacilli after intravesical BCG therapy publication-title: Urology – volume: 96 start-page: 1290 year: 2005 end-page: 3 article-title: Intravesical bacillus Calmette‐Guèrin therapy: experience with a reduced dwell‐time in patients with pronounced side‐effects publication-title: BJU Int – volume: 147 start-page: 596 year: 1992 end-page: 600 article-title: Incidence and treatment of complications of bacillus Calmette‐Guérin intravesical therapy in superficial bladder cancer publication-title: J Urol – volume: 75 start-page: 188 year: 1995 end-page: 92 article-title: The persistence of bacille Calmette‐ Guérin in the bladder after intravesical treatment for bladder cancer publication-title: Br J Urol – ident: e_1_2_7_9_2 doi: 10.1111/j.1464-410X.2005.05817.x – ident: e_1_2_7_15_2 doi: 10.1016/S0090-4295(96)00507-9 – ident: e_1_2_7_4_2 doi: 10.1016/S0022-5347(17)41212-2 – ident: e_1_2_7_3_2 doi: 10.1016/j.ctrv.2009.12.005 – ident: e_1_2_7_5_2 doi: 10.1111/j.1464-410X.1995.tb07309.x – ident: e_1_2_7_17_2 doi: 10.1016/S0022-5347(01)67606-7 – ident: e_1_2_7_2_2 doi: 10.1080/003655900750016698 – ident: e_1_2_7_7_2 doi: 10.1111/j.1445-2197.1998.tb04768.x – volume: 14 start-page: 3745 year: 2007 ident: e_1_2_7_14_2 article-title: Bladder contracture: review for intravesical bacillus Calmette‐Guérin complication publication-title: Can J Urol – ident: e_1_2_7_13_2 doi: 10.1016/0090-4295(93)90595-2 – volume: 52 start-page: 35 year: 2006 ident: e_1_2_7_8_2 article-title: Virtual cystoscopy: reality in imaging of bladder tuberculosis publication-title: J Postgrad Med – ident: e_1_2_7_10_2 doi: 10.1016/S0022-5347(17)37316-0 – ident: e_1_2_7_12_2 doi: 10.1080/00365540110077371 – ident: e_1_2_7_6_2 doi: 10.1046/j.1464-410x.1998.00578.x – ident: e_1_2_7_11_2 doi: 10.1016/S0022-5347(05)66410-5 – ident: e_1_2_7_16_2 doi: 10.1016/S1473-3099(02)00182-2 |
SSID | ssj0014665 |
Score | 2.1118727 |
Snippet | Study Type – Therapy (case series)
Level of Evidence 4
What's known on the subject? and What does the study add?
Intravesical BCG treatment has been used... • To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature. • We reviewed our database with 858 patients treated... • To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature.OBJECTIVE• To report a late bacille Calmette-Guérin... Study Type - Therapy (case series) Level of Evidence 4 OBJECTIVE: To report a late bacille Calmette-Guérin (BCG) complication previously not described in the... |
SourceID | swepub proquest pubmed pascalfrancis crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1592 |
SubjectTerms | Administration, Intravesical Aged Aged, 80 and over Antibiotics, Antitubercular - therapeutic use Antineoplastic Agents - adverse effects Bacterial diseases BCG BCG Vaccine - adverse effects Biological and medical sciences bladder neoplasm complications Cystectomy cystitis Epidemiologic Methods Human bacterial diseases Humans Infectious diseases Male Medical sciences Microbiology in the medical area Middle Aged Mikrobiologi inom det medicinska området Mycobacterium bovis - isolation & purification Nephrology. Urinary tract diseases Tuberculosis and atypical mycobacterial infections Tuberculosis, Urogenital - drug therapy Tuberculosis, Urogenital - etiology Tuberculosis, Urogenital - urine Tumors of the urinary system Urinary Bladder - microbiology Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - surgery Urinary tract. Prostate gland Urologi och njurmedicin Urology and Nephrology |
Title | Late bacille Calmette–Guérin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2010.09923.x https://www.ncbi.nlm.nih.gov/pubmed/21166754 https://www.proquest.com/docview/863768032 https://gup.ub.gu.se/publication/132360 |
Volume | 107 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELbQHhAS4h82_Kx8QNxSxbETO0dYWFYrlgOiUm-W7dortFVaNYmEOHHhCXgKnoM34UmYidNAVntYIS5RlXiadDqT-ez5PEPI82WeyWB7dj8cRKiq1Ba2SpUH9AwTImMcrkOevi-P5-JkUSwG_hPuhYn1IcYFN_SM_n2NDm5sc9HJRSpYthgYWhWAlRniScZLLKP_-sNYSQqG9l0lowjA9imp59IvmkSqmxvTgNJC7HZxGRwda41OYW4fp45uk_PdL4z0lPNZ19qZ-3Kh-OP_UcEdcmuAs_RltL-75Jqv75Hrp0PC_j759g6wLLXG4ZZDeojNWtrW__r6_W3388f2U013ZLCa4oowNXSF1HQaMMRSzATA01G7wvfjlnYr56PFUtPA2L_58HQdxnEOTXlLRxL9AzI_evPx8DgdOj-kTmBi2S8NsxKTuEWhjFPGYqU-QB7KVNLm0hbSGdyHxbnkJfMqWC5UYbwNRroQ-EOyV69rv0-oswUE3CCYNYXIl9JKxW259K5yMhNeJUTu_mXthrLo2J1jpSfTI6FRyxq1rHst688JYaPkJpYGuYLMwcSQRkEAUogFs4TQnWVpcHTM3pjar7tGqxJigcp4npBH0eL-CDNWwsRPJORFNMHxChYPP-s2Gk6ddbrxmvGcl3CXsrerKz-3fnUyx0-P_1XwCbkRV-ORKvqU7LXbzj8DONfag95RfwMrlD4n |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtNAEF6hVgIkxP-P-Sl7QNwc-WftXR-hooSS9IAaKbfV7ma3qrCcKLElxIkLT9Cn6HP0TXgSZryOwVUPFeISRclO4kxmPN_OfDtDyJtFEnGnW3Y_PDBXFKHOdBEKC-gZNkRKGcxDTo_y8YwdzrN5Nw4Iz8L4_hB9wg09o71fo4NjQvqyl7OQxdG8o2gVgFZGACh323IdIqQvfS8pWNvOlfQyANyHtJ4rP2kQq-6s1AbU5vy8i6sAad9tdAh020h1cI-U29_oCSpfR02tR-b7pfaP_0kJ98ndDtHSd94EH5AbtnpIbk67mv0j8nMCcJZqZfDUId3HeS11bX_9OPvYXJyvTyu65YNVFJPCVNES2enUYZSlWAyAy6O6xFvkmjalsd5oqdrA2r8p8XTp-nUGrXlNex79YzI7-HC8Pw674Q-hYVhbtgsVa4513CwTygilsVkfgA-hCq4TrjNuFB7FSlOe5rEVTqdMZMpqp7hxLn1CdqplZZ8RanQGMdexWKuMJQuuuUh1vrCmMDxiVgSEb_9mabrO6Digo5SDHRKTqGWJWpatluW3gMS95Mp3B7mGzN7AknpBwFIIB6OA0K1pSfB1LOCoyi6bjRQ5hAMRpUlAnnqT-yMcxzns_VhA3nob7N_B_uEnzUrCSyeN3FgZp0maw7fkrWFd-7rl-8MZPnv-r4Kvya3x8XQiJ5-OPr8gt31yHpmjL8lOvW7sK0B3td5rvfY3AXJCRQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatwwEBYlgVAo_f9xf1IdSm9e_CNb8jFNu03TJJTShb0JSZZCyOJddm0oOeWSJ8hT9Dn6Jn2Szlhetw45hNKLWWzN2js74_mk-TRDyJsyibjTLbsfDswVRagzXYTCAnqGCZFSBtchD4_yvQnbn2bTjv-Ee2F8fYh-wQ09o31fo4MvSnfVyVnI4mjaMbQKACsjwJObLIeoiQDpa19KCsa2bSW9DOD2Iavn2m8ahKo7C7UCrTnf7uI6PNoXGx3i3DZQje-R0_VP9PyU01FT65E5u1L98f_o4D652-FZuuMN8AG5ZauHZOuwy9g_IhcHAGapVgb3HNJd7NZS1_bX-eXH5ueP5UlF12ywiuKSMFV0htx06jDGUkwFwNNRPcMX5JI2M2O9yVK1grF_E-Lp3PXjDNrykvYs-sdkMv7wbXcv7Fo_hIZhZtmWKtYcs7hZJpQRSmOpPoAeQhVcJ1xn3CjciJWmPM1jK5xOmciU1U5x41z6hGxU88o-I9ToDCKuY7FWGUtKrrlIdV5aUxgeMSsCwtf_sjRdXXRszzGTg_kRk6hliVqWrZbl94DEveTC1wa5gcz2wJB6QUBSCAajgNC1ZUnwdEzfqMrOm5UUOQQDEaVJQJ56i_sjHMc5zPxYQN56E-yvYPXw42Yh4dRxI1dWxmmS5nCXvLWrGz-3fLc_wU_P_1XwNdn68n4sDz4dfX5BbvuVeaSNviQb9bKxrwDa1Xq79dnf_TJA9A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Late+bacille+Calmette%E2%80%93Gu%C3%A9rin+infection+with+a+large+focal+urinary+bladder+ulceration+as+a+complication+of+bladder+cancer+treatment&rft.jtitle=BJU+international&rft.au=Str%C3%B6ck%2C+Viveka&rft.au=Dotevall%2C+Leif&rft.au=Sandberg%2C+Torsten&rft.au=Gustafsson%2C+Christina+K%C3%A5bj%C3%B6rn&rft.date=2011-05-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=107&rft.issue=10&rft.spage=1592&rft.epage=1597&rft_id=info:doi/10.1111%2Fj.1464-410X.2010.09923.x&rft.externalDBID=10.1111%252Fj.1464-410X.2010.09923.x&rft.externalDocID=BJU9923 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |